Emergent BioSolutions Inc.

EBS

US29089Q1058

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:29:56 2024-04-26 am EDT			5-day change	1st Jan Change
1.935 ^USD	-0.77%		-5.39%	-19.58%

Apr. 24	Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	MT
Mar. 25	Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility	MT

Emergent BioSolutions Inc.(NYSE:EBS) added to Russell 2500 Value Index

June 25, 2021 at 12:00 am EDT

Latest news about Emergent BioSolutions Inc.

Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	Apr. 24	MT
Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility	Mar. 25	MT
Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility	Mar. 25	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 12	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Mar. 12	MT
Emergent BioSolutions Tumbles After S&P Global Credit Downgrade	Mar. 12	MT
Emergent BioSolutions Shares Drop on S&P Downgrade	Mar. 12	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 08	DJ
Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $5	Mar. 07	MT
News Highlights : Top Company News of the Day - Thursday at 1 AM ET	Mar. 07	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET	Mar. 06	DJ
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET	Mar. 06	DJ
News Highlights : Top Company News of the Day - Wednesday at 7 PM ET	Mar. 06	DJ
Transcript : Emergent BioSolutions Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
(EBS) EMERGENT BIOSOLUTIONS Sees Q1 Revenue Range $200M - $250M	Mar. 06	MT
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q4 Revenue $277M, vs. Street Est of $274M	Mar. 06	MT
Emergent BioSolutions Inc. Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Full Year of 2024	Mar. 06	CI
Emergent BioSolutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Emergent BioSolutions Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon	Feb. 21	MT
Top Midday Gainers	Feb. 21	MT
Emergent appoints former Bausch + Lomb CEO to head company	Feb. 21	RE
Emergent BioSolutions Appoints Joseph C. Papa as President	Feb. 21	CI
Emergent BioSolutions Inc. Announces Changes in CEO	Feb. 21	CI

Chart Emergent BioSolutions Inc.

Duration

Period

More charts

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Emergent BioSolutions Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.95 USD

Average target price

5 USD

Spread / Average Target

+156.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EMERGENT BIOSOLUTIONS INC.	-19.58%	102M
ELI LILLY AND COMPANY	+25.96%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.48%	354B
MERCK & CO., INC.	+20.25%	331B
ABBVIE INC.	+3.87%	296B
ASTRAZENECA PLC	+12.96%	233B
NOVARTIS AG	+5.57%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.38%	144B

Other Pharmaceuticals